<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: <z:chebi fb="27" ids="17992">Sucrose</z:chebi>, non-fermenting 1/<z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase-related kinase (SNARK) is involved in cellular stress responses linked to <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>We determined the role of SNARK in response to metabolic stress and insulin action on <z:chebi fb="105" ids="17234">glucose</z:chebi> and <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism in skeletal muscle </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Vastus lateralis skeletal muscle biopsies were obtained from <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant (n = 35) and type 2 diabetic (n = 31) men and women for SNARK expression studies </plain></SENT>
<SENT sid="3" pm="."><plain>Primary myotube cultures were derived from biopsies obtained from <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant individuals for metabolic studies </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: SNARK (also known as NUAK2) <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was unaltered between <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant individuals and type 2 diabetic patients </plain></SENT>
<SENT sid="5" pm="."><plain>SNARK expression was increased in skeletal muscle from <z:mp ids='MP_0001261'>obese</z:mp> (BMI &gt;31 kg/m(2)) <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant individuals and type 2 diabetic patients (1.4- and 1.4-fold, respectively, p &lt; 0.05) vs overweight (BMI &lt;28 kg/m(2)) <z:mpath ids='MPATH_458'>normal</z:mpath> <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerant individuals and type 2 diabetic patients </plain></SENT>
<SENT sid="6" pm="."><plain>SNARK <z:chebi fb="2" ids="33699">mRNA</z:chebi> was increased in myotubes exposed to <z:chebi fb="2" ids="29889">palmitate</z:chebi> (12-fold; p &lt; 0.01), or TNF-alpha (25-fold, p &lt; 0.05), but not to <z:chebi fb="0" ids="30823">oleate</z:chebi>, <z:chebi fb="105" ids="17234">glucose</z:chebi> or IL-6, whereas expression of the <z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-activated protein kinase alpha2 subunit was unaltered </plain></SENT>
<SENT sid="7" pm="."><plain>Small interfering (si)<z:chebi fb="40" ids="33697">RNA</z:chebi> against SNARK reduced <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein in myotubes by 61% and 60%, respectively (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain>SNARK siRNA was without effect on basal or insulin-stimulated <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake or <z:chebi fb="23" ids="18059">lipid</z:chebi> oxidation, and insufficient to rescue TNF-alpha- or <z:chebi fb="2" ids="29889">palmitate</z:chebi>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS/INTERPRETATION: Skeletal muscle SNARK expression is increased in human <z:hpo ids='HP_0001513'>obesity</z:hpo>, and in response to metabolic stressors, but not type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>Partial SNARK <z:mpath ids='MPATH_63'>depletion</z:mpath> failed to modify either <z:chebi fb="105" ids="17234">glucose</z:chebi> or <z:chebi fb="23" ids="18059">lipid</z:chebi> metabolism, or protect against TNF-alpha- or <z:chebi fb="2" ids="29889">palmitate</z:chebi>-induced <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> in primary human myotubes </plain></SENT>
</text></document>